[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Taiwan University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":634},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,445,0,25,[9,43,71,95,122,149,172,194,221,248,269,303,324,349,374,401,427,451,482,508,531,556,581,601,619],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100652790","group-based-brief-behavioral-therapy-for-insomnia-for-patients-with-chronic-mental-illness-100652790",false,"NCT07779499","Group-Based Brief Behavioral Therapy for Insomnia for Patients With Chronic Mental Illness","Effectiveness of a Group-Based Brief Behavioral Therapy for Insomnia for Patients With Chronic Mental Illness","Inclusion Criteria:\n\n* Aged 18 years and older.\n* Diagnosed with a psychiatric disorder.\n* Experiencing self-reported sleep disturbances, such as difficulty initiating sleep, difficulty maintaining sleep, early morning awakening, prolonged sleep latency, short sleep duration, poor sleep efficiency, or the current use of sedative-hypnotic medications.\n\nExclusion Criteria:\n\n* Severe intellectual disability resulting in the inability to complete the assessment questionnaires.\n* Severe cognitive impairment (e.g., dementia) that prevents cooperation and participation in the intervention activities.\n* Recent clinical instability, high suicide risk, or deemed unsuitable for participation by the primary attending physician.","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the effectiveness of a short-term, group-based Brief Behavioral Therapy for Insomnia (BBTI) intervention in chronic psychiatric patients at a hospital day ward.The main questions it aims to answer are:\n\n1. Does the BBTI-based group intervention improve subjective sleep quality and reduce the severity of insomnia?\n2. Does the intervention have a positive effect on psychological well-being and cardiometabolic\u002Fphysical functions? Researchers will compare an experimental group to a waitlist control group to see if the intervention improves sleep quality, reduces insomnia-perpetuating behaviors, and enhances overall health status across various timeframes.\n\nParticipants will:\n\n1. Attend four sessions that cover sleep structure education, relaxation techniques (including acupressure), sleep-promoting diet principles, and the proper use of sedative-hypnotic medications.\n2. Write a daily sleep diary.\n3. Complete three times of structured self-report questionnaires.\n4. Undergo physiological and physical function assessments.",[27],"Insomnia",[29,30],"brief behavioral treatment of insomnia","insomnia","NOT_YET_RECRUITING","2026-08-18",{"date":34,"type":35},"2026-08-21","ACTUAL",{"date":37,"type":21},"2026-08-31",{"date":39,"type":21},"2026-11-10",{"name":41,"class":42},"National Taiwan University Hospital","OTHER",{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100547528","high-definition-transcranial-electrical-stimulation-for-upper-extremity-rehabilitation-100547528","NCT06409143","High-definition Transcranial Electrical Stimulation for Upper Extremity Rehabilitation","Neural Mechanisms and Augmented Efficacy of High-definition Transcranial Electrical Stimulation on Upper-extremity Function in Patients With Subacute Stroke","Inclusion Criteria:\n\n\\- Sub-Project 1 (Healthy)\n\n1. Adults aged 18 and above.\n2. Confirmed right-handedness using the Edinburgh Handedness Inventory.\n\nSub-Project 1 (Post-stroke patients)\n\n1. Aged 18 and above.\n2. Diagnosed with stroke.\n3. Post-stroke for more than 6 months.\n4. Unilateral hemiparesis.\n\nSub-Project 2 (Subacute-stroke patients)\n\n1. Aged 18 and above.\n2. Diagnosed with stroke.\n3. Stroke occurred between 7 days to 6 months ago.\n4. Unilateral hemiparesis.\n5. Degree of recovery for proximal and distal movements of the affected upper limb is Brunnstrom stage III to V.\n6. No severe muscle spasticity in any segments of the affected upper limb (Modified Ashworth Scale ≤ 2).\n\nExclusion Criteria:\n\n\\- Sub-Project 1 (Healthy)\n\n1. History of neurological disorders (e.g., stroke, brain tumor, epilepsy), psychiatric disorders (e.g., substance abuse, major depression, schizophrenia, bipolar disorder), or musculoskeletal disorders of the upper limb.\n2. Contraindications to transcranial electrical stimulation, including history of epilepsy, atrial fibrillation, presence of metal implants, cardiac pacemakers, convexity skull defects, or increased intracranial pressure.\n3. Skin allergies, contact dermatitis, abnormal pain, hypersensitivity to pain, wounds, or ulcers on the head.\n4. Participation in other invasive or non-invasive brain stimulation research studies.\n5. Pregnancy or lactating women. (If female, must be postmenopausal or surgically sterilized. Fertile women must have a negative pregnancy test result. Fertile female patients engaging in heterosexual intercourse, as well as fertile male patients with fertile female partners, must agree to use effective contraception during the trial period and for 4 months after the last dose of the investigational drug, such as oral contraceptives, dual barrier methods, intrauterine devices, or abstain from sexual intercourse during this period; non-fertile women are those who have undergone bilateral oophorectomy or are postmenopausal.)\n6. History of alcohol or substance abuse.\n7. Damaged skin at the stimulation site, electrode contact, or device wearing site.\n8. Long-term use of central nervous system affecting medications (such as antidepressants, sedatives) or other medications that may affect seizure threshold.\n9. Other conditions deemed unsuitable for transcranial electrical or magnetic stimulation by a physician.\n10. Affiliation with any research institution\u002Fexecution unit (e.g., students from NTU, Taipei Medical University).\n\nSub-Project 1 (Post-stroke patients)\n\n1. Contraindications to transcranial electrical stimulation include a history of epilepsy, atrial fibrillation, presence of metal implants, cardiac pacemakers, convexity skull defects, or increased intracranial pressure.\n2. Skin allergies, contact dermatitis, abnormal pain, hypersensitivity to pain, wounds, or ulcers on the head.\n3. Severe neurological or psychiatric disorders other than stroke (such as major depression, schizophrenia, substance abuse, organic brain diseases, Parkinson's disease, brain tumors).\n4. Use of medications that may lower the seizure threshold.\n5. Undergoing other invasive or non-invasive brain stimulation therapies.\n6. Pregnancy or lactating women. (If female, must be postmenopausal or surgically sterilized. Fertile women must have a negative pregnancy test result. Fertile female patients engaging in heterosexual intercourse, as well as fertile male patients with fertile female partners, must agree to use effective contraception during the trial period and for 4 months after the last dose of the investigational drug, such as oral contraceptives, dual barrier methods, intrauterine devices, or abstain from sexual intercourse during this period; non-fertile women are those who have undergone bilateral oophorectomy or are postmenopausal.)\n7. History of alcohol or substance abuse.\n8. Damaged skin at the stimulation site, electrode contact, or device wearing site.\n9. Long-term use of central nervous system affecting medications (such as antidepressants, sedatives) or other medications that may affect seizure threshold.\n10. Other conditions deemed unsuitable for transcranial electrical or magnetic stimulation by a physician.\n\nSub-Project 2 (Subacute-stroke patients)\n\n1. Contraindications to transcranial electrical stimulation include a history of epilepsy, atrial fibrillation, presence of metal implants, cardiac pacemakers, convexity skull defects, or increased intracranial pressure.\n2. Skin allergies, contact dermatitis, abnormal pain, hypersensitivity to pain, wounds, or ulcers on the head.\n3. Severe neurological or psychiatric disorders other than stroke (such as major depression, schizophrenia, substance abuse, organic brain diseases, Parkinson's disease, brain tumors).\n4. Use of medications that may lower the seizure threshold.\n5. Other muscle and joint problems affecting upper limb function, such as joint contractures, rheumatoid arthritis, myositis ossificans.\n6. Severe cognitive impairment or receptive or global aphasia making it difficult to understand instructions.\n7. Hemineglect (including visual, auditory, or sensory neglect).\n8. Undergoing other invasive or non-invasive brain stimulation therapies.\n9. Pregnancy or lactating women. (If female, must be postmenopausal or surgically sterilized. Fertile women must have a negative pregnancy test result. Fertile female patients engaging in heterosexual intercourse, as well as fertile male patients with fertile female partners, must agree to use effective contraception during the trial period and for 4 months after the last dose of the investigational drug, such as oral contraceptives, dual barrier methods, intrauterine devices, or abstain from sexual intercourse during this period; non-fertile women are those who have undergone bilateral oophorectomy or are postmenopausal.)\n10. History of alcohol or substance abuse.\n11. Damaged skin at the stimulation site, electrode contact, or device wearing site.\n12. Long-term use of central nervous system affecting medications (such as antidepressants, sedatives) or other medications that may affect seizure threshold.\n13. Other conditions deemed unsuitable for transcranial electrical or magnetic stimulation by a physician.",true,{"count":52,"type":21},152,[24],"Upper limb hemiparesis is the most common sequelae in patients, severely impacting their independence and quality of life. Transcranial electrical stimulation (tCES) is a non-invasive and safe treatment, which uses a low direct current or alternating current to change the excitability of the cerebral cortex. It can induces long-term potentiation-like or long-term depression-like effects, thereby modulating the cortical excitability. In recent years, researchers have developed high-definition (HD) devices, which integrate high definition ring electrode configurations and incorporate direct current with theta burst stimulation waveforms. Diverging from traditional transcranial direct current stimulation (tDCS), which applies weak currents (0.5-2 mA) through two large sponge electrodes (25\\~35 cm\\^2) externally to the scalp for widespread non-specific cortical stimulation, HD-tES employs an array of small-area electrodes (1 cm\\^2) to control current distribution over localized cortical regions, thereby enhancing spatial accuracy. However, there is a lack of studies validating the optimal waveform for HD-tES, as well as clinical evidence in subacute stroke populations. The optimal unilateral versus bilateral stimulation modes and their neurological mechanisms for stroke rehabilitation also remain uncertain.",[56],"Stroke",[56,58,59,60,61],"High-Definition Transcranial Electrical Stimulation","Upper-limb rehabilitation","Transcranial electrical stimulation","Neuroplasticity","RECRUITING",{"date":64,"type":35},"2026-08-20",{"date":66,"type":35},"2024-08-15",{"date":68,"type":21},"2027-11-30",{"name":41,"class":42},3,{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100449774","inflammatory-marker-and-pre-existing-venous-fibrosis-to-predict-avf-mal-maturation-100449774","NCT05136859","Inflammatory Marker and Pre-existing Venous Fibrosis to Predict AVF Mal-maturation","Inclusion Criteria:\n\n1. Age of 20 and older adult patients.\n2. preoperatively clinical and ultrasound assessment of the arm vessels are visible for the creation of a native HDAVF that include：the augmented diameters of the veins is \\> 2.0 mm and the diameter of the radial artery is\\> 2.0 mm. Besides, there is no obvious stenosis of vessels in the forearm.\n\nExclusion Criteria:\n\n1. The patient refused to join the study\n2. serious heart failure (Physicians identify insufficient cardiac output that may affect sacral blood flow development after surgery)\n3. Unconsciousness\n4. Bedridden for long time\n5. systemic lupus erythematosus(SLE), or other known autoimmune diseases\n6. The physician excludes the possibility of creating a wrist HDAVF before surgery\n7. Surgeon preoperatively identifies vessel inadequacy for the creation of a wrist HDAVF\n8. Choose a site other than the wrist for surgery\n9. Unexpected complications happen during the surgery that prevent the completion of a wrist HDAVF","20 Years",{"count":79,"type":21},100,[24],"End-stage renal disease patients needs a functional vascular access to receive hemodialysis and prolong their lives. Arteriovenous fistula (AVF) is priority consideration for hemodialysis, which is a connecting a superficial vein to a nearby artery and allowing this vein to enlarge and increase in internal diameter under arterial circulation. Unfortunately, 30-50% of fistulae fail to mature. Vascular calcification and stenosis were considered for early failure. The perivascular fat of artery can be predicted successful AVF maturation. However, Few previous studies have compared AVF maturation between perivascular the fat of cephalic vein or removal during the AVF surgery. This study evaluated whether the effect of AVF inflammation and preexisting vascular fibrosis is associated to perivascular the fat of cephalic vein. Investigators will also verify inflammation by analysis of blood and tissue samples, the association of pre-existing fibrosis, and the clinical correlation with AVF early failure.\n\nThis study will enroll patients with chronic kidney disease stage 5 and stage 6 who will need maintenance-hemodialysis (HD) from Nov 2021 to Dec 2022. Investigators will use the preoperative ultrasound assessment tool to confirm the feasibility of the arm vessels for the creation of a native AVF. As a prospective randomized controlled trial of perivascular fat preservation or removal during the AVF surgery, a study assistant will help the randomization and explain the informed consent to the patient . The subjects are randomly split into two groups: the experimental group will have the perivascular fat of the target cephalic vein preserved the control group will have the fat removed before the AVF anastomosis. The survey will enroll 100 adult patients and categorize them into groups according to each AVF maturation, JAS, or FTM (see definition below) by 3 - 12 after the surgery.",[83],"Arteriovenous Fistula",[85,86,83,87],"hemodialysis","Inflammation","perivascular fat",{"date":64,"type":35},{"date":90,"type":35},"2021-12-11",{"date":92,"type":21},"2026-12-31",{"name":41,"class":42},1,{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":17,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":120,"leadSponsor":121,"locationsCount":94},"100652591","social-robots-and-board-games-for-children-with-autism-spectrum-disorder-100652591","NCT07775937","Social Robots and Board Games for Children With Autism Spectrum Disorder","Effectiveness of Social Robot-Assisted Intervention Combined With Board Games on Socio-Emotional Skills in Children With Autism Spectrum Disorder: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Children aged 4 to 10 years, of any biological sex.\n2. Confirmed clinical diagnosis of Autism Spectrum Disorder (ASD).\n3. Cognitive ability: Comprehensive Developmental Inventory for Infants and Toddlers (CDIIT) results indicating borderline to normal cognitive function, with a Developmental Quotient (DQ) \\>= 70.\n4. Socio-emotional ability: CDIIT socio-emotional subscale indicating borderline development, with a Developmental Quotient (DQ) between 70 and 84.\n5. Legal guardian provides written informed consent and child provides assent where appropriate.\n\nExclusion Criteria:\n\n1. Inability to comprehend or engage in interactive activities involving the Kebbi Air robot or physical board games.\n2. Presence of other primary diagnoses affecting emotional or social functioning, such as severe neurodevelopmental disorders, psychiatric disorders, or ASD with severe emotional disturbances that prevent participation in intervention activities (CDIIT DQ \\\u003C 70).\n3. Inability to commit to regular weekly intervention sessions, or parental unwillingness to participate in required observational assessments and questionnaire completion.\n4. Strong behavioral resistance or severe aversion to digital interactive tools or board game activities.\n5. Inability to follow simple two-step verbal instructions after a preliminary 10-minute trial assessment conducted by the occupational therapist.","4 Years","10 Years",{"count":105,"type":21},20,[24],"This pilot randomized controlled trial evaluates the effectiveness of combining social robot-assisted intervention with physical board games to improve socio-emotional skills in children with Autism Spectrum Disorder (ASD).\n\nChildren with ASD often face challenges in emotion recognition, emotional regulation, and social interaction. This study aims to investigate whether integrating an interactive social robot (Kebbi) into board game activities can enhance children's social engagement, emotional comprehension, and cooperative behaviors compared to conventional occupational therapy. Participants will be randomly assigned to either the robot-assisted board game group or the conventional occupational therapy group.",[109,110],"Autism Spectrum Disorder","Child Development Disorders, Pervasive",[112,113,114,115,116],"Social Robots","Board Games","Occupational Therapy","Socio-Emotional Skills","Emotion Recognition","2026-08-17",{"date":64,"type":35},{"date":32,"type":35},{"date":92,"type":21},{"name":41,"class":42},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":94},"100652217","medial-prefrontal-cortex-brain-magnetic-stimulation-in-autism-100652217","NCT07770451","Medial Prefrontal Cortex Brain Magnetic Stimulation in Autism","The Efficacy and Brain Mechanism of Deep Transcranial Magnetic Stimulation in Autism: A Pilot Study Targeting Medial Prefrontal Cortex","Inclusion Criteria:\n\n* Having a diagnosis of autism spectrum disorder based on DSM-5-TR diagnosis criteria\n* Aged 18-45 years old\n* No change of medications in the past three months\n\nExclusion Criteria:\n\n* Comorbidity of schizophrenia, substance use disorder,\n* Had major medical diseases (e.g., malignancy, severe cardiac, hepatic, renal diseases, or active CNS or systemic infection) or major neurological disease (e.g., uncontrolled epilepsy, brain tumors or hemangioma, severe head trauma)\n* Contraindications of MRI or TMS procedure: Ferromagnetic material in the skull, head, and neck; claustrophobia; had received neurosurgery, etc.\n* Receiving electroconvulsive therapy or TMS in the past three months","45 Years",{"count":105,"type":21},[24],"Despite decades of research, no definitive, effective biological treatments exist for core symptoms of Autism Spectrum Disorder (ASD). Emerging evidence suggests that conventional Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex or posterior superior temporal sulcus may reduce repetitive behaviors, but its efficacy on social communication remains inconsistent.\n\nDeep Transcranial Magnetic Stimulation (dTMS) allows for the stimulation of deeper brain structures. Deep social brain networks, such as the medial prefrontal cortex (mPFC), play a critical role in social cognition and mentalizing processes. Targeting the mPFC with dTMS holds potential for improving core impairments in social cognition among individuals with ASD. This pilot study aims to evaluate the efficacy of dTMS on social cognition, mPFC-related functional connectivity, and clinical symptoms (autism severity, stereotyped behaviors, sensory symptoms, and emotion regulation).",[109],[135,136,137,138,139,140,141,142],"autism spectrum disorder","asd","Deep Transcranial Magnetic Stimulation","dTMS","Medial Prefrontal Cortex","mPFC","brain stimulation","neuromodulation",{"date":32,"type":35},{"date":145,"type":21},"2026-12-01",{"date":147,"type":21},"2028-12-31",{"name":41,"class":42},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100611686","comparison-of-mixed-reality-and-ultrasound-localization-techniques-for-surgical-stabilization-of-rib-fractures-100611686","NCT07243808","Comparison of Mixed Reality and Ultrasound Localization Techniques for Surgical Stabilization of Rib Fractures","Inclusion Criteria:\n\n1. Ages 18 to 80 years\n2. Computed tomography (CT) demonstrates ≥3 rib fractures, and the patient meets indications for surgical stabilization of rib fractures (SSRF).\n3. Able to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Uncorrected coagulopathy.\n2. Known osteoporosis or pathologic fractures.\n3. Respiratory failure or hemodynamic instability requiring emergent surgery.\n4. Declines to participate or withdraws consent.","80 Years",{"count":157,"type":21},30,"OBSERVATIONAL","The goal of this observational study is to compare two localization methods used before surgical stabilization of rib fractures (SSRF): mixed reality (MR) and ultrasound-guided.\n\nMain Research Question Before SSRF, does MR help surgeons mark rib fracture locations more accurately (in centimeters) and faster than ultrasound-guided?\n\nParticipants After the study ends, all participants will keep follow-up at the thoracic surgery clinic. The team will record wound healing and pain scores for use in the observational study.",[161],"Surgical Stabilization of Rib Fracture",[163,164],"Ultrasound-guided localization","Mixed reality",{"date":166,"type":35},"2026-08-19",{"date":168,"type":21},"2026-09-01",{"date":170,"type":21},"2027-10-29",{"name":41,"class":42},{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":94},"100652558","a-mixed-methods-analysis-of-the-six-core-competencies-and-ai-literacy-reflected-in-medical-students-self-assessment-during-small-group-discussions-100652558","NCT07775885","A Mixed-Methods Analysis of the Six Core Competencies and AI Literacy Reflected in Medical Students' Self-Assessment During Small-Group Discussions","Inclusion Criteria:\n\n* Reports from the fourth-year medical students who completed an integrated pathology and pharmacology small-group discussion course at National Taiwan University during the 2023-2026 academic years.\n\nExclusion Criteria:\n\n* Reports containing fewer than 300 words or lacking substantive reflection will be excluded.",{"count":179,"type":21},450,"This study aims to examine how the six Accreditation Council for Graduate Medical Education (ACGME) core competencies and AI literacy are reflected in medical students' self-assessment narratives following small-group discussions. A mixed-methods design will be used to analyze approximately 500 de-identified self-assessment reflection reports submitted by fourth-year medical students who completed an integrated pathology and pharmacology small-group discussion course at National Taiwan University during the 2023-2026 academic years.",[182,183],"Core Competency","Reflective Thinking",[185,186,187],"Accreditation Council for Graduate Medical Education (ACGME)","core competencies","AI literacy","2026-08-16",{"date":64,"type":35},{"date":191,"type":21},"2026-08-15",{"date":147,"type":21},{"name":41,"class":42},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":209,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},"100652545","effectiveness-of-implementing-a-reablement-model-in-community-based-long-term-care-centers-100652545","NCT07775781","Effectiveness of Implementing a Reablement Model in Community-Based Long-Term Care Centers","Inclusion Criteria:\n\n* Aged 18 years or older and assessed as CMS Level 2 or above.\n* Regularly receiving adult day care services and attending at least two days per week.\n* Able to understand simple instructions and participate in activities with assistance.\n\nExclusion Criteria:\n\n* Severe cognitive impairment or severe visual or hearing impairment that interferes with participation in activities or assessments.\n* A major fall within the past three months or acute symptoms that prevent participation in assessments or study procedures.\n* Concurrent participation in another intensive rehabilitation program or research intervention.\n* Clear unwillingness to participate in the study intervention or inability to complete the three-month intervention period.",{"count":201,"type":21},300,[24],"This study will examine whether a reablement approach can help people receiving community-based long-term care maintain or improve their independence, daily functioning, and quality of life. Approximately 300 adults from eight long-term care facilities across Taiwan will participate. The 12-week reablement program includes group and individualized activities designed to support mobility, cognitive function, daily activities, and social participation. Participants' physical and cognitive function, daily living abilities, emotional well-being, quality of life, and personal goals will be assessed before and after the program.\n\nThe study will also include observations and interviews with care providers, participants, and family members to understand their experiences with the program and identify factors that support successful implementation. The findings are expected to help develop a practical reablement model for community-based long-term care in Taiwan and provide guidance for improving care quality, independence, and healthy aging.",[205,206,207,208],"Elderly","Long-Term Care","Reablement","Activities of Daily Living",[210,211,212,213],"reablement","activities of daily living","long-term care","daycare center",{"date":64,"type":35},{"date":216,"type":35},"2026-07-01",{"date":218,"type":21},"2028-12",{"name":41,"class":42},8,{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":50,"sex":228,"minAge":18,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":236,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":94},"100638984","virtual-forest-based-mindfulness-for-perinatal-mental-health-100638984","NCT07606248","Virtual Forest-Based Mindfulness for Perinatal Mental Health","Evaluating the Effects of an Integrated Virtual Forest Environment and Mindfulness-Based Intervention on Mental Health in Perinatal Women","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* Gestational age below 25 weeks at recruitment\n* Able to communicate in Chinese and provide informed consent\n* Willing to participate in the study and complete follow-up assessments\n\nExclusion Criteria:\n\n* Diagnosed epilepsy, photosensitive epilepsy, or other neurological disorders\n* Severe anxiety, depression, or other psychiatric disorders currently receiving intensive treatment\n* History of severe adverse reactions to virtual reality devices, including severe dizziness, nausea, or visual discomfort\n* Inability to participate in mindfulness or VR intervention proceduresriteria:\n\nExclusion Criteria:\n\n\\-","FEMALE",{"count":79,"type":21},[24],"Perinatal anxiety and depression are common mental health concerns that may negatively affect maternal well-being, infant development, and family functioning. Mindfulness-based interventions have shown beneficial effects on reducing psychological distress during pregnancy; however, maintaining attention and engagement during mindfulness practice may be challenging for some pregnant women.\n\nThis randomized controlled trial aims to evaluate the feasibility and effectiveness of an integrated virtual forest environment and mindfulness-based intervention for improving mental health in perinatal women. Pregnant women between 20 and 24 weeks of gestation will be randomly assigned to either an experimental group receiving virtual reality (VR)-based forest mindfulness intervention or a control group receiving conventional mindfulness intervention.\n\nBoth groups will participate in a 9-week mindfulness program and receive app-based mindfulness practice. The experimental group will additionally receive immersive VR forest-based mindfulness sessions during prenatal visits. Outcomes including anxiety, depression, mindfulness awareness, physiological indicators, and intervention acceptability will be assessed during pregnancy and postpartum follow-up.",[233,234,235],"Perinatal Anxiety","Perinatal Depression","Maternal Mental Health",[237,238,239,240,241],"Virtual reality","Mindfulness","Forest therapy","Perinatal mental health","Pregnancy",{"date":32,"type":35},{"date":244,"type":35},"2026-06-16",{"date":246,"type":21},"2027-12-31",{"name":41,"class":42},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":94},"100428455","the-holistic-health-care-of-post-cardiac-arrest-survivors-from-patients-health-to-family-resilience-100428455","NCT04859270","The Holistic Health Care of Post-Cardiac Arrest Survivors: From Patient's Health to Family Resilience","Inclusion Criteria:\n\n1\\. Patients with non-traumatic cardiac arrest, who have successfully sustained return of spontaneous circulation for more than five minutes after resuscitation efforts.\n\nExclusion Criteria:\n\n1. Under 20 years of age\n2. Pregnant\n3. Terminally ill cancer patients or cancer patients who are unwilling to receive treatment\n4. When the ICU is over capacity and unable to provide intensive care.\n5. The patient or family members refused to participate in this study.",{"count":255,"type":21},600,"Post-cardiac arrest mortality remains high and proper care after cardiopulmonary resuscitation is an important clinical challenge. This prospective observational cohort aims to (1) identify the factors that affect short-term and long-term survival in post-cardiac arrest survivors and (2) investigate the patients and their families' health-related quality of life and psychological well-being.",[258],"Post-Cardiac Arrest Syndrome",[260,261,262],"Post-cardiac arrest","Holistic care","Family resilience",{"date":32,"type":35},{"date":265,"type":35},"2021-04-12",{"date":267,"type":21},"2027-03-31",{"name":41,"class":42},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":285,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":94},"100652105","assessing-outcomes-of-three-different-museum-based-social-prescription-programs-in-autistic-adults-100652105","NCT07768332","Assessing Outcomes of Three Different Museum-based Social Prescription Programs in Autistic Adults","Exploring the Feasibility of Social Prescription in People on the Autism Spectrum","Inclusion Criteria:\n\n* Meet the diagnostic criteria for autism spectrum disorder.\n* Have intellectual functioning within the normal range.\n* Be willing and able to participate in the study procedures.\n* Be willing to attend the relevant museum activities and group discussions, when applicable.\n* Agree to audio and video recording during relevant study activities.\n\nExclusion Criteria:\n\n* Are unwilling to complete the required assessments.\n* Have a serious physical or psychiatric condition that limits their physical stamina, emotional capacity, or ability to understand and complete the study procedures.\n* Refuse audio or video recording.","50 Years",{"count":278,"type":21},90,[24],"This study will examine whether visiting the National Taiwan Museum can support the social and emotional well-being of autistic adults.\n\nThe research team plans to recruit 90 autistic adults aged 18 to 50 from the Department of Psychiatry at National Taiwan University Hospital. Participants must have average-range intellectual ability and be able and willing to complete the study activities and assessments. People with serious physical or mental health conditions that would prevent full participation will not be included. Participants must also agree to audio and video recording during the activities.\n\nAfter an outpatient doctor confirms eligibility, participants will complete questionnaires and choose one of three museum participation options:\n\n1. Visit the museum once independently.\n2. Join five guided museum visits with group discussions.\n3. Invite a friend to visit the museum together.\n\nEach group will include about 30 participants.\n\nFor the guided group, each session will last about 90 minutes and include a professional museum tour, a question-and-answer period, time for independent exploration, and a group discussion. Participants will be encouraged to select exhibits that interest them, record their observations, share their thoughts, listen to others, and respond to different viewpoints.\n\nThe five planned museum themes include Taiwan's history and identity, relationships between people and nature, architecture and living spaces, human evolution and the future, and attitudes toward money and financial planning. The discussions will explore everyday topics such as stereotypes, personal values, preferred living environments, hopes for the future, and managing money.\n\nParticipants will complete questionnaires before and after the program. These questionnaires will assess areas such as autistic characteristics, social communication, empathy, sensory experiences, comfort with social touch, emotional skills, loneliness, anxiety, depression, and anxiety during social interaction. Participants will also rate how enjoyable, comfortable, safe, interesting, and socially engaging they found the museum activities.\n\nThe researchers will compare participants' results before and after the program. They will also compare the three participation options to determine whether independent visits, guided group activities, or visiting with a friend produce different outcomes.\n\nThe overall goal is to understand whether museum-based activities can be used as a form of social prescribing to improve social participation, emotional well-being, confidence, and quality of life among autistic adults.",[282,283,284],"Autism Spectrum Disorder (ASD","Autism","Autistic Spectrum Disorder (ASD)",[286,287,288,289,290,291,292,293,294,295],"Autism spectrum disorder","ASD","autism","psychosocial intervention","social participation","community-based intervention","cultural participation","autistic adults","social prescribing","museum-based intervention","2026-08-13",{"date":117,"type":35},{"date":299,"type":35},"2024-05-01",{"date":301,"type":21},"2027-12",{"name":41,"class":42},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":228,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":323,"locationsCount":94},"100651644","enhanced-recovery-after-surgery-eras-in-patients-undergoing-gynecologic-surgery-100651644","NCT07764276","Enhanced Recovery After Surgery (ERAS) in Patients Undergoing Gynecologic Surgery","The Effect of Enhanced Recovery After Surgery (ERAS) Program in Patients Undergoing Gynecologic Surgery","Inclusion Criteria:\n\n* Female scheduled for laparotomic gynecologic surgery (including hysterectomy, myomectomy, adenomyomectomy, oophorectomy or oophrocystectomy, staging surgery, debulking surgery or interval debulking surgery)\n* 18 years old or older\n* American Society of Anesthesiologists Physical Status classification I to III.\n\nExclusion Criteria:\n\n* Female undergo laparoscopic surgery but are converted to laparotomic surgery\n* History of delayed gastric emptying, gastrointestinal motility disorders or chronic pain\n* Female undergo emergent surgery.",{"count":311,"type":21},200,[24],"Enhanced Recovery After Surgery (ERAS) is a multidisciplinary perioperative care program designed to reduce surgical stress, accelerate postoperative recovery, and improve clinical outcomes. This prospective, non-randomized study aims to evaluate the effectiveness of an ERAS program in patients undergoing gynecologic surgery at National Taiwan University Hospital Hsin-Chu Branch. Patients who choose to participate in the ERAS program will receive perioperative care according to the institutional ERAS protocol, while those who choose conventional perioperative care will serve as the comparison group. Perioperative outcomes, postoperative recovery, postoperative complications, pain scores, and other clinical outcomes will be compared between the two groups to evaluate the clinical impact of implementing an ERAS program.",[315,316,317],"ERAS","Gynecologic Surgery","Gynecologic Oncological Pelvic\u002FAbdominal Surgery","2026-08-12",{"date":296,"type":35},{"date":321,"type":35},"2024-05-16",{"date":301,"type":21},{"name":41,"class":42},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":331,"maxAge":103,"enrollmentInfo":332,"targetDuration":4,"studyType":22,"phases":333,"briefSummary":334,"conditions":335,"keywords":339,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":346,"leadSponsor":348,"locationsCount":94},"100601219","exploring-perceptual-learning-in-blurred-gabor-discrimination-for-low-myopic-children-100601219","NCT07107646","Exploring Perceptual Learning in Blurred Gabor Discrimination for Low-Myopic Children","Investigating the Efficacy of Perceptual Learning in Blurred Gabor Discrimination Among Children With Low Myopia: An Exploratory Study","Experimental and Control Group\n\nInclusion Criteria:\n\n1. Children aged between 6 to 10 years.\n2. Best corrected distance visual acuity of 6\u002F6 or 0.00 logMAR.\n3. Diagnosed with low myopia after a comprehensive ophthalmologic examination, with a spherical equivalent refractive error ranging from -0.50 to -1.25 diopters, including up to -0.75 diopters of astigmatism.\n4. Not currently undergoing any of the four standard myopia control treatments for children:\n\n   1. Atropine (mydriatic agent)\n   2. Orthokeratology\n   3. Peripheral defocus soft contact lenses\n   4. Peripheral defocus spectacle lenses (frame glasses)\n5. Willing and able to provide informed consent, and able to comply with study procedures and assessments.\n\nExclusion Criteria:\n\nParticipants will be excluded if they have any of the following ophthalmologic conditions:\n\n1. Strabismus\n2. Binocular vision problems\n3. Ocular diseases\n4. History of ocular surgery (excluding refractive surgery)","6 Years",{"count":157,"type":21},[24],"This exploratory study investigates whether perceptual learning using blurred Gabor stimuli can improve uncorrected distance visual acuity in children aged 6-10 years with low myopia. Participants will be randomly assigned to a training group or control group. The training group will undergo individualized visual perceptual learning through a digital Vision Training System (VTS) for approximately 3 months. The study will also evaluate changes in refraction, contrast sensitivity, visual crowding, Chinese reading acuity with eye movements, and sweep visual evoked potentials (sVEPs).",[336,337,338],"Myopia","Visual Rehabilitation","Perceptual Learning",[340,338,341,342],"Low Myopia","Visual Acuity","Visual Evoked Potentials",{"date":344,"type":35},"2026-08-14",{"date":168,"type":21},{"date":347,"type":21},"2027-07-31",{"name":41,"class":42},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":356,"maxAge":18,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":358,"briefSummary":359,"conditions":360,"keywords":364,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":94},"100570005","in-person-and-telehealth-visual-rehabilitation-for-children-with-low-vision-100570005","NCT06701617","In-person and Telehealth Visual Rehabilitation for Children With Low Vision","The Effectiveness of In-person and Telehealth Visual Rehabilitation for Children With Low Vision","Passive visual stimulation group\n\nInclusion Criteria:\n\n1. Children aged less than or equal to 18 years old.\n2. The causes of visual disorder in children are unlimited.\n3. The acuity of the children's better eye was ≤ 0.2.\n4. Children with multiple disabilities and visual disorders typically exhibit developmental levels ranging from moderate to severe or below.\n5. The parents of these children exhibit a positive attitude and are willing to cooperate with visual learning programs.\n6. Infants under 1 year old with low vision without other developmental issues , under or equal to moderate developmental issues.\n\nExclusion Criteria:\n\n1. Significant refractive errors that affect acuity but are unable to cooperate with wearing corrective glasses in two training sessions.\n2. Requires patching for monocular vision rehabilitation but is unable to cooperate with patching in two training sessions.\n3. The individual is unable to adapt to the training environment and cooperate with visual learning in two sessions due to unstable emotions or difficulty adapting to the environment.\n\nPerceptual learning group Inclusion Criteria\n\n(1)Children aged less than or equal to 12 years old. (2)No restrictions on the causes of visual impairment in children. (3)The acuity of the children's better eye was ≤ 0.5 (4)If children have additional developmental issues, their disability severity should primarily be mild or moderate.\n\n(5)The primary caregiver demonstrates a positive attitude and is willing to cooperate with the visual training program.\n\n(6)The child is capable of completing calibration with an eye-tracking device. Exclusion Criteria\n\n1. Significant refractive errors that severely affect vision, where the child cannot adapt to wearing corrective glasses within two training sessions.\n2. Requires occlusion therapy for monocular visual rehabilitation but cannot cooperate with occlusion within two training sessions.\n3. Inability to adapt to the training environment or cooperate with visual training due to emotional instability or difficulty adjusting within two training sessions.\n4. Unstable physiological conditions (e.g., epilepsy, sleep disturbances) that prevent consistent participation in visual training.","1 Month",{"count":311,"type":21},[24],"Restorative visual rehabilitation is frequently used to enhance the visual development and function of children with low vision. An important strategy within this field is visual stimulation, which is particularly used for infants and toddlers with low vision, as well as for children who have both developmental disabilities and low vision.This study has two primary objectives.The first objective is to examine the effect of using intensive, specific, and flickering black-and-white checkerboard patterns to enhance visual function in children with mild to moderate low vision. The second objective is to develop a visual stimulation program tailored for children with severe or profound multiple disabilities and visual impairments, and to evaluate its effectiveness. For both objectives, the visual stimulation intervention will be provided through either in-person or remote delivery",[337,361,362,363,338],"Oddball Design","Cerebral Visual Impairment","Passive Visual Stimulation",[365,366,367],"visual rehabilitation","visual stimulation","perceptual learning",{"date":344,"type":35},{"date":370,"type":35},"2024-11-25",{"date":372,"type":21},"2028-06-14",{"name":41,"class":42},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":398,"leadSponsor":400,"locationsCount":4},"100616821","effects-of-a-visual-interactive-line-chatbot-on-self-management-of-egfr-tki-related-side-effects-in-patients-with-lung-cancer-100616821","NCT07310589","Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients With Lung Cancer","A Randomized Controlled Trial to Evaluate the Effects of a Visual-Interactive LINE Chatbot on Self-Management of EGFR-TKI-Related Side Effects in Patients With Lung Cancer","Inclusion Criteria:\n\n* Patients with newly diagnosed stage IIIB to IVB unresectable or inoperable non-small cell lung cancer (NSCLC), or those with first disease recurrence who are receiving oral targeted therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, with the ability to perform self-care activities.\n* Patients receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy, including gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib.\n* Willingness to participate in the study, with completion of the informed consent process and provision of written informed consent.\n* Ability to communicate in Chinese and to independently operate a smartphone and use the LINE application.\n\nExclusion Criteria:\n\n* Patients diagnosed with a second primary malignancy or multiple malignancies.\n* Patients receiving other anticancer treatments.",{"count":382,"type":21},178,[24],"This study aims to evaluate a visual interactive LINE chatbot designed to support self-management of treatment-related side effects among patients with advanced lung cancer receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy.\n\nPatients receiving EGFR-TKI treatment often experience long-term side effects that require ongoing self-management. In this randomized controlled trial, participants will be assigned to receive either usual care alone or usual care plus access to the LINE chatbot intervention, which provides visualized and interactive educational content for symptom monitoring and self-care.\n\nThe primary outcome of this study is self-management ability related to EGFR-TKI-associated side effects. Secondary outcomes include quality of life during treatment and overall satisfaction with the LINE chatbot intervention.",[386],"Non-Small Cell Lung Cancer",[388,389,390,391,392,393],"LINE Chatbot","EGFR-TKIs","side effects","Self-management ability","Quality of life","NSCLC","2026-08-10",{"date":396,"type":35},"2026-08-11",{"date":191,"type":21},{"date":399,"type":21},"2028-06-30",{"name":41,"class":42},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":331,"maxAge":408,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":414,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":424,"leadSponsor":426,"locationsCount":94},"100651491","non-wearable-audiovisual-distraction-for-childrens-medical-anxiety-in-the-ed-100651491","NCT07761637","Non-Wearable Audiovisual Distraction for Children's Medical Anxiety in the ED","Effectiveness of Non-Wearable Immersive Audiovisual Distraction in Alleviating Pediatric Anxiety in Emergency Department: A Stratified Randomized Controlled Trial","Inclusion Criteria:\n\n* Pediatric patients aged 6 to 12 years presenting to the Emergency Department.\n* Requiring invasive medical procedures (e.g., blood sampling, intravenous line insertion, or laceration repair\u002Fsuturing).\n* Patient and legal guardian\u002Fparent willing and able to provide informed assent\u002Fconsent and comply with study protocols.\n\nExclusion Criteria:\n\n* Patients with severe developmental delay, cognitive impairment, or neurological disorders affecting communication or behavioral assessment.\n* Patients with severe visual or hearing impairment that prevents interaction with the non-wearable display system.\n* Hemodynamically unstable patients or those requiring immediate life-saving resuscitation.\n* Patients with severe upper body or facial injuries that prevent the placement or operation of continuous ECG recorders.","12 Years",{"count":278,"type":21},[24],"Pediatric emergency department (ED) visits often cause significant anxiety and stress for young patients due to unfamiliar environments and invasive medical procedures. Non-pharmacological interventions, such as distraction, are vital for reducing pediatric anxiety and improving procedural outcomes.\n\nThis study evaluates the effectiveness of a non-wearable, immersive audiovisual distraction system (LG StanbyME display) in alleviating pediatric anxiety during emergency department care, compared to standard care.\n\nThe main questions it aims to answer are:\n\nDoes non-wearable audiovisual distraction reduce anxiety levels in pediatric emergency patients compared to standard care?\n\nDoes the intervention improve physiological indicators of distress, such as Heart Rate Variability (HRV)?\n\nParticipants will:\n\nBe randomly assigned to either the non-wearable audiovisual distraction group or the routine care group.\n\nUndergo continuous physiological monitoring (HRV) and clinical anxiety assessment (mYPAS-SF) during their ED visit.",[413],"Pediatric Anxiety",[415,416,417,418,419,420],"Audiovisual Distraction","Pediatric Emergency Medicine","Heart Rate Variability","Non-Wearable Technology","mYPAS-SF","Procedural Pain and Anxiety","2026-08-09",{"date":318,"type":35},{"date":168,"type":21},{"date":425,"type":21},"2027-09-30",{"name":41,"class":42},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":437,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":4},"100651144","investigating-modulation-of-neuropathic-pain-by-transcranial-magnetic-stimulation-a-multimodal-imaging-and-electrophysiological-approach-100651144","NCT07758348","Investigating Modulation of Neuropathic Pain by Transcranial Magnetic Stimulation: a Multimodal Imaging and Electrophysiological Approach","INVESTIGATING MODULATION OF NEUROPATHIC PAIN BY TRANSCRANIAL MAGNETIC STIMULATION: A MULTIMODAL IMAGING AND ELECTROPHYSIOLOGICAL APPROACH","Inclusion Criteria:\n\n* 1\\. Age 18 or older and 90 or younger. 2. Ability to give informed consent. 3. Independent in activity of daily living. 4. Neuropathic pain secondary to peripheral neuropathy (including hereditary neuropathies). The diagnosis of peripheral neuropathy is confirmed by a neurologist, based on clinical symptoms and at least one of the following objective criteria:\n\n  1. Nerve conduction study: reduced compound muscle action potential (CMAP) or sensory nerve action potential (SNAP) (peroneal nerve: CMAP \\\u003C 2 mV, tibial nerve: CMAP \\\u003C 6.1 mV, and sural nerve: SNAP \\\u003C 5 microV), or prolonged distal motor latencies (\\> 5.5 ms), or slowing of motor or sensory nerve conduction velocities (\\\u003C 40 m\u002Fs), or prolonged minimal F latencies (\\> 50 ms) in two or more nerves in the lower limbs.\n  2. Autonomic function test:\n\n     (i) absent sympathetic skin response (SSR); or (ii) reduced R-R interval variability (RRIV) during rest or forced deep breathing, below age-adjusted thresholds (rest\u002Fdeep breathing: 12%\u002F19% for age 20 \\~ 29 years; 6%\u002F9% for age 30 \\~ 39 years; 6%\u002F14% for age 40 \\~ 49 years; 5%\u002F11% for age 50 \\~ 59 years; and 7%\u002F8% for age not less than 60 years).\n  3. Quantitative sensory test: abnormal warm or cold threshold at the foot (warm\u002Fcold thresholds: \\> 38.6 °C \u002F\\\u003C 27.5 °C for age \\\u003C 40 years, \\> 40.1 °C\u002F\\\u003C 26.7 °C for age 40 \\~ 59 years, and \\> 40.6 °C\u002F\\\u003C 27.0 °C for age not less than 60 years).\n  4. Skin biopsy: reduced intraepidermal nerve fiber density at the distal leg (\\\u003C 5.88 fibers\u002Fmm for age \\\u003C 60 years, and \\\u003C 2.50 fibers\u002Fmm for age not less than 60 years).\n\n  5\\. Agree not to take caffeine, alcohol, tea and drugs with significant nervous system effects for 48 hours before each study session.\n\nExclusion Criteria:\n\n* 1\\. Presence of severe systemic diseases, including severe heart disease, severe lung diseases with dyspnea, severe generalized edema, systemic infection, and uncontrolled migraines due to high intracranial pressure.\n\n  2\\. Presence of major neurological disorders, including brain tumor, head trauma, and infection or inflammation of the nervous system.\n\n  3\\. History of epilepsy or family history of seizure disorder. 4. Presence of neurodegenerative disorders involving the brain or spinal cord. 5. Patients suffering from multiple sclerosis. 6. Individuals with large areas of ischemic scarring. 7. Skin damage or lesions on the area of the body to be stimulated (the head). 8. Presence of psychiatric disorders diagnosed by a psychiatrist that may interfere with the subjective assessment of pain, including (i) major depressive disorder with a PHQ-9 score not less than 20 (indicating a severe episode; Kroenke et al. (2001)); (ii) anxiety disorder with a GAD-7 score not less than 15 (at a severe level; Spitzer et al. (2006)), or (iii) post-traumatic stress disorder with a PCL-5 score not less than 32 (exhibiting frequent flashbacks or hyperarousal symptoms; Zuromski et al. (2019)).\n\n  9\\. Individuals with suicidal ideation within the past year. 10. Presence of implanted medical devices such as a cardiac pacemaker, implantable cardioverter-defibrillator (ICD), cochlear implant, implanted neurostimulator, implanted drug delivery pump, spinal or ventricular drainage device, aneurysm clips, or any metallic foreign object in the body, unless these devices are certified as compatible with MRI or TMS.\n\n  11\\. Current use of any medication known to lower the seizure threshold. 12. History of sleep disorders during previous TMS sessions. 13. Pregnancy 14. Claustrophobia or any other contraindications to MRI 15. Inability to give informed consent. 16. Drug abuse and alcoholism","90 Years",{"count":436,"type":21},52,[24],"The proposed project will combine functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) to identify neurobiological mechanisms underlying how repetitive transcranial magnetic stimulation (rTMS) applied to the primary motor cortex modulates maladaptive neuroplasticity following neuropathic pain.",[440],"Patients With Neuropathic Pain Due to Peripheral Neuropathy",[442,443],"neuropathic pain","Transcranial magnetic stimulation","2026-08-06",{"date":396,"type":35},{"date":447,"type":21},"2026-09",{"date":449,"type":21},"2030-07",{"name":41,"class":42},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":461,"briefSummary":463,"conditions":464,"keywords":466,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":94},"100649897","phase-3-osimertinib-with-or-without-primary-lung-tumor-resection-for-egfr-mutant-oligometastatic-non-small-cell-lung-cancer-100649897","NCT07738172","Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer","A Multicenter, Randomized Controlled Phase III Clinical Trial of Primary Tumor Resection in Patients With Oligometastatic EGFR-Mutant Non-Small Cell Lung Cancer After EGFR-Targeted Therapy","PTR-2","This study consists of 2 screening phases:\n\nPart 1 screening (before osimertinib induction):\n\nPatients must meet the baseline eligibility criteria, including stage IV NSCLC, EGFR sensitizing mutation (exon 19 deletion or L858R), resectable dominant primary lung lesion, and adequate performance status and organ function.\n\nPart 2 screening (after 12 weeks of protocol-defined osimertinib induction and before randomization):\n\nPatients must complete 12 weeks of osimertinib 80 mg once daily and undergo restaging evaluation. Only patients with partial response (PR) or stable disease (SD) by RECIST 1.1, and who remain suitable for thoracic surgery, will proceed to randomization.\n\nDisease distribution must satisfy all of the following: no more than 3 involved organs, one dominant pulmonary primary lesion, the maximal diameter of the dominant primary lung lesion greater than any individual distant metastatic lesion, and a total number of distant metastatic lesions fewer or equal than 10. Pleural or peritoneal metastasis confined to a single cavity and amenable to treatment may be considered a single metastatic lesion.\n\nInclusion criteria for screening part 1\n\n1. Histologically or cytologically confirmed NSCLC.\n2. Age ≥18 years.\n3. AJCC 8th edition stage IV NSCLC.\n4. EGFR sensitizing mutation limited to exon 19 deletion or exon 21 L858R.\n5. WHO performance status 0-1. Patients with brain metastases must be conscious; patients with bone metastases must not have irreversible severe events such as severe pathological fracture.\n6. Disease distribution meeting all of the following criteria:\n\n   1. no more than 3 involved organs;\n   2. one dominant pulmonary primary lesion;\n   3. the maximal diameter of the dominant pulmonary primary lesion is greater than any single distant metastatic lesion;\n   4. total number of distant metastatic lesions fewer or equal to 10.\n7. The primary lung tumor is considered resectable by the investigator and thoracic surgeon, with surgery intended for maximal regional control.\n8. The patient is able to take oral medication and is expected to receive first-line osimertinib induction therapy.\n9. Major organ function and pulmonary reserve are adequate to tolerate the planned surgery.\n10. After 12 weeks of protocol-defined osimertinib induction, the patient must have PR or SD by RECIST 1.1 and remain eligible for randomization.\n\nInclusion Criteria for Screening Part 2\n\nSubjects may proceed to randomization only if all of the following criteria are met:\n\n1. The subject has received first-line protocol-defined osimertinib induction according to the study protocol, consisting of osimertinib once daily (QD) for 12 weeks, and has completed the pre-randomization evaluation.\n2. Restaging imaging has been completed after 12 weeks of induction therapy, and the response is assessed as partial response (PR) or stable disease (SD) according to RECIST version 1.1. In addition, the maximal diameter of the target primary lung tumor before surgery must be greater than the sum of the maximal diameters of the metastatic tumors. PET-CT before surgery or before randomization is recommended to evaluate for newly developed extrathoracic metastases, bone metastases, or mediastinal lymph node involvement. If PET-CT is not performed, the preoperative or pre-randomization imaging assessment should include contrast-enhanced CT scans of the chest and abdomen, including the liver and adrenal glands; brain imaging should be completed with contrast-enhanced CT or MRI. Pleural or peritoneal metastasis confined to a single cavity (for example, unilateral pleural disease) and amenable to treatment may be considered a single metastatic lesion.\n\nIf either of the following conditions is present on restaging imaging:\n\n1. the sum of the longest diameters (SLD) of the primary lung tumor after treatment falls within the range of less than 30% decrease and less than 20% increase (that is, -30% \\\u003C SLD change \\\u003C +20%); or\n2. the total number of distant metastatic lesions is 6 to 10, then the treatment response of the other distant target metastatic lesions must additionally meet an SLD reduction of at least 30% in order for the subject to remain eligible for randomization.\n\n   4\\. Estimated life expectancy is greater than 3 months, as judged by the investigator.\n\n   5\\. The subject remains suitable for primary lung tumor resection, as assessed by the investigator and thoracic surgeon, and has no major comorbidity that would increase surgical risk to an unacceptable level.\n\n   Exclusion criteria Subjects meeting any of the following criteria will be excluded from this study. If any of these conditions are identified only after completion of the 12-week induction phase, the subject will not proceed to randomization.\n   1. Pathology other than non-small cell lung cancer (NSCLC), or failure to meet the EGFR mutation criteria specified in this study.\n   2. EGFR mutation other than exon 19 deletion or exon 21 L858R.\n   3. Involvement of more than 3 organs by tumor lesions.\n   4. Total number of distant metastatic lesions greater than 10.\n   5. No clearly dominant primary pulmonary lesion, or the maximal diameter of the dominant primary pulmonary lesion is not greater than any individual distant metastatic lesion.\n   6. Diffuse pleural or peritoneal carcinomatosis that cannot be clearly localized and treated with local definitive therapy.\n   7. Progressive disease (PD) on imaging evaluation after 12 weeks of protocol-defined osimertinib induction.\n   8. Judged by the investigator or thoracic surgeon to be no longer suitable for thoracic surgery after induction therapy.\n   9. Any systemic therapy other than the protocol-defined osimertinib induction for the current stage IV NSCLC.\n   10. Any prior EGFR-TKI, chemotherapy, immunotherapy, or other systemic anticancer therapy for the current stage IV NSCLC, except for the protocol-defined osimertinib induction.\n   11. Pregnant, breastfeeding, or planning pregnancy during the study period.\n   12. Any condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study, or highly likely to be unable to comply with the study procedures, restrictions, or requirements.",{"count":460,"type":21},154,[462],"PHASE3","Osimertinib is a standard first-line treatment for patients with metastatic non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 deletion or exon 21 L858R mutation. Although osimertinib can provide effective disease control, most patients eventually experience disease progression, and the primary lung tumor may remain an important site of treatment resistance.\n\nThis multicenter, randomized, open-label phase III trial will evaluate whether surgical removal of the primary lung tumor, in addition to continued osimertinib treatment, prolongs progression-free survival in patients with EGFR-mutated oligometastatic non-small cell lung cancer.\n\nAll participants will initially receive osimertinib 80 mg orally once daily for 12 weeks. Participants who have a partial response or stable disease according to RECIST version 1.1 and remain suitable for surgery will be randomly assigned in a 1:1 ratio to continue osimertinib alone or to undergo primary lung tumor resection followed by resumption of osimertinib. The study will also evaluate overall survival, safety, pathologic response, quality of life, patterns of disease progression, and changes in molecular biomarkers.",[465],"Lung Neoplasms, Non-Small Cell Lung Cancer",[467,468,469,470,471,472,473],"non-small cell lung cancer (NSCLC)","EGFR mutation","stage IV non-small-cell lung cancer","Osimertinib","Primary tumor resection","Oligometastatic non-small cell lung cancer","Local consolidative therapy","2026-08-05",{"date":476,"type":35},"2026-08-07",{"date":478,"type":21},"2026-08-01",{"date":480,"type":21},"2031-08-01",{"name":41,"class":42},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":50,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":489,"targetDuration":356,"studyType":158,"phases":4,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":94},"100650226","knee-ligament-stiffness-across-ethnicities-before-and-after-osteoarthritis-treatment-100650226","NCT07744789","Knee Ligament Stiffness Across Ethnicities Before and After Osteoarthritis Treatment","Across Ethnicities of Norm of Knee Ligament Stiffness and Its Association With Osteoarthritis Before\u002FAfter Treat-ment: a Sonoelastography Model","Inclusion Criteria\n\n* Healthy volunteers:\n* Adults aged 20 years or older.\n* Able to understand the study procedures and provide written informed consent.\n* Able to ambulate independently without walking aids.\n* No pain in either knee during the previous 6 months.\n* Patients with symptomatic knee osteoarthritis:\n* Adults aged 20 years or older.\n* Able to understand the study procedures and provide written informed consent.\n* Pain in at least one knee during the previous year.\n* Knee pain, soreness, or stiffness documented within the previous month.\n* Radiographic knee osteoarthritis defined by at least one of the following:\n* Kellgren-Lawrence grade ≥2 on anteroposterior radiographs.\n* Kellgren-Lawrence grade ≥2 on skyline radiographs.\n* Superior or inferior patellar osteophytes or posterior tibial osteophytes on lateral radiographs.\n\nExclusion Criteria\n\n* Healthy volunteers:\n* Previous knee surgery.\n* Rupture of any cruciate or collateral ligament.\n* Major knee or periarticular trauma.\n* Rheumatic or autoimmune disease.\n* Diagnosis of knee osteoarthritis within the previous 6 months.\n* Patients with symptomatic knee osteoarthritis:\n* Rheumatic or autoimmune disease.\n* Malignancy.\n* Previous major knee trauma or knee surgery.\n* Corticosteroid injection into the affected knee within the previous 3 months.",{"count":490,"type":21},208,"This prospective clinical study aims to establish normative values of knee ligament stiffness across different ethnic populations using shear wave elastography (SWE) and to investigate biomechanical alterations associated with knee osteoarthritis (OA). Healthy adults and patients with symptomatic knee OA will undergo standardized SWE examinations of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), medial collateral ligament (MCL), and lateral collateral ligament (LCL), together with clinical assessments. For patients who subsequently receive clinically indicated ultrasound-guided injection therapy, follow-up SWE and clinical evaluations will be performed to investigate changes in ligament stiffness after treatment.",[493],"Knee Osteoarthritis",[493,495,496,497,498,499,500],"Shear Wave Elastography","Anterior Cruciate Ligament","Posterior Cruciate Ligament","Medial Collateral Ligament","Lateral Collateral Ligament","Ultrasound","2026-08-04",{"date":444,"type":35},{"date":504,"type":35},"2023-07-26",{"date":506,"type":21},"2027-12-01",{"name":41,"class":42},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":22,"phases":517,"briefSummary":518,"conditions":519,"keywords":521,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":529,"locationsCount":530},"100521403","comparisons-of-treatment-responses-of-early-syphilis-to-benzathine-penicillin-g-with-or-without-doxycycline-100521403","NCT06069141","Comparisons of Treatment Responses of Early Syphilis to Benzathine Penicillin G With or Without Doxycycline","Comparisons of Treatment Responses of Early Syphilis to 2.4 Milliunits (MU) Single-dose Benzathine Penicillin G With or Without Doxycycline in People Living With HIV","Inclusion Criteria:\n\n* People living with HIV (PLWH) aged ≥18 years with early syphilis\n* Confirmed by a positive RPR titer with a reactive TPPA assay\n\nExclusion Criteria:\n\n* PWH with RPR titers of \\\u003C4\n* Subject has latent syphilis of unknown duration, late latent syphilis, or evidence of neurosyphilis, including ocular involvement.\n* Exposure to antibiotics with activity against T. pallidum within the preceding 4 weeks (penicillin, 3rd cephalosporin, doxycycline, macrolides)\n* A known or suspected infection requiring additional treatment with an antimicrobial active against T. pallidum at baseline (penicillin, 3rd cephalosporin, doxycycline, macrolides)\n* A history of intolerance to penicillin or doxycycline\n* PLWH have already participated in this study\n* Pregnancy",{"count":516,"type":21},688,[24],"This randomized controlled superiority study will be conducted during 2023-2025. The eligible participants are adult people living with HIV (PLWH) who are newly diagnosed with early syphilis. Participants will be randomized in a 1:1 ratio to receive single-dose benzathine penicillin G (BPG) (2.4 MU intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days) or single-dose BPG. The primary outcome is serologic response, defined as a decline of rapid plasma reagin (RPR) titer by 4-fold or greater, at week 24 and week 48; and the secondary outcomes include microbiologic response of syphilis and bacterial sexually transmitted infections (STIs) assessed by nucleic-acid amplification test (NAAT) at week 4.",[520],"Early Syphilis, Latent, Serological Relapse After Treatment",[522,523],"syphilis","rapid plasma reagin","2026-08-03",{"date":444,"type":35},{"date":527,"type":35},"2024-01-01",{"date":147,"type":21},{"name":41,"class":42},9,{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":50,"sex":17,"minAge":539,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":542,"conditions":543,"keywords":547,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":553,"completionDateStruct":554,"leadSponsor":555,"locationsCount":94},"100647037","consensus-and-norms-for-medical-visualization-academic-standards-study---a-modified-delphi-study-100647037","NCT07684703","Consensus And Norms for Medical Visualization Academic Standards Study - A Modified Delphi Study","The CANVAS (Consensus And Norms for Medical Visualization Academic Standards) Study: Developing Professional Standards for Effective Medical Visualization - A Modified Delphi Study","CANVAS","Experts were invited from medical illustration training programs or professional associations worldwide. Inclusion criteria required that invitees meet at least one of the following conditions:\n\nInclusion Criteria:\n\n* Current faculty or staff at one of the accredited degree-granting institutions in medical and scientific illustration\n* Current member of a nationally\u002Fregionally recognized medical illustration association\n* Holder of the Certified Medical Illustrator (CMI) credential issued by the Board of Certification of Medical Illustrators\n* Current visualization editor or supervisor at a high-impact medical journal.\n* Required to possess at least five years of professional experience in medical visualization or a related discipline\n* Willing to complete the Delphi questionnaire, having provided informed consent prior to questionnaire commencement.\n\nExclusion Criteria:\n\n* Prior participation in the focus group or validity assessment stages of this study's initial questionnaire development\n* Direct financial interest in commercial AI medical imaging products or related services\n* Inability to complete the questionnaire in the designated language (English) in the absence of a corresponding language version.\n\nIndividuals meeting any of the above criteria were excluded to preserve the independence of the consensus process.","27 Years",{"count":541,"type":21},50,"The goal of this observational study (modified Delphi consensus study) is to establish an international expert consensus on professional standards for medical visualization in medical visualization experts from from around the world, each with a minimum of five years of relevant professional experience. The specific objectives are:\n\n1. to develop and validate core consensus statements on professional standards for medical visualization (consensus threshold ≥75%).\n2. to quantify the distribution of divergence in professional opinion.\n\nParticipants will:\n\nFill out a short background survey about their job title, training, work setting, location, and experience with AI image tools.\n\nRate 10 statements about medical visualization standards on a scale from 1 (Strongly Disagree) to 5 (Strongly Agree). These statements cover three topics: accuracy, accessibility, and ethics. Participants will complete up to 3 rounds of anonymous online surveys.\n\nWrite comments to explain why they disagree with any statement they rate 1 or 2.\n\nBetween rounds, review a summary showing their own earlier ratings and the group's overall results (with no names attached). Then, re-rate any statements the group has not yet agreed on.",[544,545,546],"Medical Visualization","Medical Illustration","Consensus",[544,548,549,550],"Medical illustration","Modified Delphi method","Expert consensus","2026-08-02",{"date":501,"type":35},{"date":191,"type":21},{"date":246,"type":21},{"name":41,"class":42},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":22,"phases":564,"briefSummary":565,"conditions":566,"keywords":570,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":578,"leadSponsor":580,"locationsCount":94},"100650216","effects-of-a-self-regulation-based-e-mote-program-delivered-via-an-ai-assisted-robot-and-supported-by-mobile-platforms-for-newly-diagnosed-gynecologic-cancer-patients-100650216","NCT07745478","Effects of a Self-Regulation Based E-MOTE Program Delivered Via an AI-Assisted Robot and Supported by Mobile Platforms for Newly Diagnosed Gynecologic Cancer Patients","Effects of a Self-Regulation-Based E-MOTE Emotional Care Program Delivered Via an AI-Assisted Robot and Supported by Mobile Platforms for Newly Diagnosed Gynecologic Cancer Patients From Surgery to 6-Month Post-Discharge","\\*\\*\\*Patients\\*\\*\\*\n\nInclusion Criteria:\n\n* Aged 18 years or older.\n* Diagnosed with gynecologic cancer and undergoing surgery.\n* Willing to receive E-MOTE robot and wear a smart wearable device.\n* Willing to complete pre-test and post-test questionnaires.\n\nExclusion Criteria:\n\n* Unable to communicate clearly.\n* Unwilling or unable to participate in the study in its entirety.\n\n\\*\\*\\*Nurse\\*\\*\\*\n\nInclusion Criteria:\n\n* Aged 18 years or older.\n* As a clinical nurse and has cared for patients who received the E-MOTE robot\n\nExclusion Criteria:\n\n\\- Unwilling to participate in the qualitative interview.",{"count":20,"type":21},[24],"To evaluate the effectiveness of the E-MOTE Emotional Care Program, delivered through the Kebbi robot and the LINE Official Account, for patients newly diagnosed with gynecologic cancer undergoing surgery. The primary outcomes are psychological distress , and the secondary outcomes are physical symptoms, stress index, and quality of life.",[567,568,569],"Nursing","Gynecological Cancers","Psycho-Oncology",[571,572,573,574],"Artifical inteligence","Robot","Emotional assessment","Psychological support","2026-07-30",{"date":501,"type":35},{"date":168,"type":21},{"date":579,"type":21},"2028-07-31",{"name":41,"class":42},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":276,"enrollmentInfo":587,"targetDuration":4,"studyType":22,"phases":589,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":94},"100649445","applying-low-intensity-focused-ultrasound-in-treating-severe-substance-use-disorder-tolerability-and-effectiveness-100649445","NCT07734623","Applying Low-Intensity Focused Ultrasound in Treating Severe Substance Use Disorder: Tolerability and Effectiveness","Inclusion Criteria:\n\n* Meets the DSM-5 criteria for opioid use disorder or amphetamine use disorder, with a severity level of severe, and does not currently meet the criteria for in sustained remission;\n* Within 7 days prior to the screening assessment, the participant must have been receiving a stable dose of medication treatment, such as methadone, buprenorphine\u002Fnaloxone, or naltrexone;\n* Within 7 days prior to the screening assessment, the participant must have abstained from illicit substances and alcohol, and must have a negative urine drug test;\n* The bilateral nucleus accumbens must be clearly identifiable on magnetic resonance imaging (MRI), such that they are sufficient for treatment targeting and for indirect measurement from other anatomical structures;\n* The participant must be able to communicate effectively and express their feelings and experiences during the study procedures;\n* The participant must be willing to comply with the study requirements, including adherence to prescribed medications and cooperation with study visits and assessments.\n\n(The participant must have the capacity to make independent medical decisions, as determined by the clinical team.)\n\nExclusion Criteria:\n\n* Presence of neurological disorders or major psychiatric disorders, such as acute-phase schizophrenia spectrum disorder, acute-phase bipolar disorder, acute-phase major depressive disorder, severe cognitive impairment, or recent suicidal ideation or plan;\n* Antisocial personality disorder;\n* Occurrence of major physical health problems within 6 months prior to the trial, including: Cardiovascular or hemodynamic abnormalities, such as heart failure, arrhythmia, tachycardia or bradycardia (\\>100 bpm or \\\u003C60 bpm), abnormal systolic blood pressure (\\>180 mmHg or \\\u003C90 mmHg), or abnormal diastolic blood pressure (\\>180 mmHg); Platelet or coagulation abnormalities (INR \\> 1.5) or current use of medications that may cause anticoagulation, such as warfarin or Avastin; Renal dysfunction (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or ongoing hemodialysis; Severe infection; Immunocompromised status; History of intracranial hemorrhage, intracranial aneurysm, cerebrovascular events within the past 6 months, or brain tumor; Neurological diseases, such as stroke, epilepsy, Parkinson's disease, dementia, or related disorders; Any other physical illness that, based on clinical evaluation, may pose a significant risk to physical function or life during treatment.\n* Participants who, upon evaluation, are deemed unsuitable for MR-guided focused ultrasound treatment, including those with a low skull density ratio (\\\u003C0.4), intracranial implants, or energy-absorbing structures or sensitive tissues along the ultrasound beam path that cannot be avoided (such as prior ventriculoperitoneal shunt sites, surgical metal clips, significant calcifications, extensive scarring, or any rigid implants). During the pre-treatment evaluation, a head CT scan will be performed to determine whether the skull density ratio is suitable for focused ultrasound treatment. Based on prior theoretical evidence, an excessively low skull density ratio may reduce the efficiency of MR-guided focused ultrasound and increase the risk of adverse effects, and therefore such participants are considered unsuitable for focused ultrasound treatment.\n* Structural abnormality of either side of the nucleus accumbens;\n* Contraindications to MRI, such as claustrophobia, allergy to MRI contrast agents, or the presence of metallic implants incompatible with MRI;\n* Contraindications to PET imaging, such as allergy to radiopharmaceutical contrast agents;\n* Inability to comply with trial-related instructions, lack of legal\u002Fbehavioral capacity, or lack of motivation to receive treatment;\n* Pregnancy or breastfeeding;\n* Scalp atrophy or poor wound healing of the scalp;\n* Any other condition that, in the physician's judgment, makes the participant unsuitable for enrollment in the clinical trial.",{"count":588,"type":21},60,[24],"The goal of this clinical trial is to investigate the safety and efficacy of applying low-intensity focused ultrasound targeting the nucleus accumbens in individuals with opioid or amphetamine use disorders. The main questions it aims to answer is:\n\n\\- Low-intensity focused ultrasound targeting the nucleus accumbens demonstrates sufficient safety and predictable therapeutic efficacy in individuals with opioid or amphetamine use disorders.\n\nParticipants will:\n\n* Received Low-intensity focused ultrasound neuromodulation once\n* Visit the clinic for checkups and asessment at 1 week, 1 month, 3 months, 6 months, 9 months, 1 year, 1.5 years, and 2 years after received Low-intensity focused ultrasound neuromodulation.",[592,593],"Opioid Use Disorder, Severe","Amphetamine Use Disorder",{"date":595,"type":35},"2026-07-31",{"date":597,"type":35},"2025-01-01",{"date":599,"type":21},"2030-12-31",{"name":41,"class":42},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":608,"targetDuration":610,"studyType":158,"phases":4,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":618,"locationsCount":94},"100549376","care-needs-in-lung-cancer-patients-receiving-immunotherapy-100549376","NCT06433206","Care Needs in Lung Cancer Patients Receiving Immunotherapy","Quality of Life, Symptom Severity, and Care Needs in Lung Cancer Patients Receiving Immunotherapy","Inclusion Criteria:\n\n1. Individuals diagnosed with malignant lung tumors based on imaging or post-surgical histopathological examination results by specialized physicians.\n2. Individuals who have received immunotherapy in the past or are currently undergoing immunotherapy.\n3. Research participants who are conscious, aged 20 years or older, able to communicate in Mandarin or Taiwanese, capable of completing the questionnaire, willing to participate in the study, and have signed the research consent form.\n\nExclusion Criteria:\n\n1. Individuals with significant cognitive impairments who are unable to complete the questionnaire.\n2. Individuals who are unable to communicate in Mandarin or Taiwanese.",{"count":609,"type":21},180,"1 Day","Lung cancer ranks as the leading cause of cancer-related deaths globally and is among the most common malignancies. In recent years, the advancements in immune checkpoint inhibitors have marked a significant breakthrough in the immunotherapy of lung cancer. However, immunotherapy is a relatively new treatment modality, and ongoing clinical trials continue to explore its efficacy. Due to a lack of knowledge about immunotherapy-related care, patients often experience uncertainty and anxiety regarding its effectiveness, resulting in associated care needs.\n\nA total of 160 lung cancer patients were included in the study. The research findings revealed statistically significant correlations (p \\\u003C 0.05) between the severity of disease, symptomatology, overall health status, functional capacity, cognitive function, disease progression, mood, and general supportive care needs, as well as specific needs of lung cancer patients.\n\nRegarding factors influencing care needs, it was found that general supportive care needs were significantly influenced by marital status, average personal monthly income, and disease progression. Additionally, age, surgical history, functional capacity, and cognitive function significantly influenced specific care needs. Based on these statistical findings, it is crucial for nursing staff to closely monitor changes in patients' symptoms and mood and provide timely care and support. Furthermore, future interventions should focus on addressing the heightened needs of lung cancer patients, thereby reducing their dissatisfaction along the cancer treatment journey.",[613],"Lung Cancer, Immunotherapy, Quality of Life, Symptom Severity, Care Needs",{"date":595,"type":35},{"date":616,"type":35},"2021-04-21",{"date":246,"type":21},{"name":41,"class":42},{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":276,"enrollmentInfo":625,"targetDuration":4,"studyType":22,"phases":626,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":633,"locationsCount":94},"100507243","the-plasticity-of-social-brain-network-in-adults-with-autism-spectrum-disorder-100507243","NCT05884853","The Plasticity of Social Brain Network in Adults With Autism Spectrum Disorder","Inclusion Criteria:\n\n* age between 18 and 50\n* diagnosed with ASD from licensed mental health or medical professional based on DSM5\n* have social problems\n* motivated to participate in the treatment\n* fluent in chinese\n* caregiver also fluent in chinese and motivated to participate\n* had a full-scale IQ \\> 70 on WAIS-IV\n* scored ≧ 26 on the caregiver-reported Autism Spectrum Quotient (AQ), indicating clinical impairment associated with ASD.\n\nExclusion Criteria:\n\n* history of major mental illness, such as bipolar affective disorder, schizophrenia, psychosis, or neurological diseases\n* visual impairment and\u002For hearing impairment\n* any metal, electronic part that cannot be removed from the body, or being pregnant, which may not be able to use fMRI scan.",{"count":20,"type":21},[24],"\"Social brain\" refers to brain regions dedicated to processing social information and enabling us to recognize and evaluate others' mental states. The social brain hypothesis suggests that our brains evolve to navigate complex social systems. The social brain is hypothesized to consist of a distributed network including the posterior superior temporal sulcus (pSTS), the dorsal and ventral medial prefrontal cortices (dmPFC and vmPFC), ACC and posterior cingulate cortex (PCC), the amygdala, the orbital frontal cortex (OFC), and the fusiform gyrus (FG), TPJ, inferior occipital gyrus (IOG), and the insula. Each region serves distinct role while works together to support social processing, including perceiving, interpreting, and generating responses to the intentions, dispositions, and behaviors of others.",[109],{"date":595,"type":35},{"date":631,"type":35},"2021-01-01",{"date":246,"type":21},{"name":41,"class":42},""]